Headshot photo of Dennis Bourdette, M.D., FANA, FAAN

Dennis Bourdette, M.D., FANA, FAAN

  • Professor Emeritus of Neurology, School of Medicine
  • Neuroscience Graduate Program, School of Medicine
  • Jungers Center for Neurosciences Research


Dr. Bourdette was previously chair of the Department of Neurology, Roy and Eulalia Swank family research professor, executive director of the OHSU Multiple Sclerosis Center and co-director of the VA MS Center of Excellence-West. He directs a team dedicated to curing and treating diseases such as multiple sclerosis, Alzheimer’s, Parkinson’s, stroke, and ALS.

He is nationally recognized for his important discoveries in the field of multiple sclerosis and oversees an annual research budget of over $2 million. His team has attracted grants from the National Institutes of Health, Department of Veterans Affairs, National MS Society, Nancy Davis Foundation for Multiple Sclerosis, to name a few. He and his colleagues have received international attention for their development of a TCR peptide vaccine called Neurovax for the treatment of multiple sclerosis and a new therapy called VG1000 being developed with a local biotechnology company, Virogenomics. Dr. Bourdette received his medical degree at the University of California at Davis, joined OHSU in 1984 as a resident in the Department of Neurology.

Education and training

  • Degrees

    • M.D., 1978, University of California-Davis Medical School
  • Residency

    • Medicine – Santa Clara Valley Medical Center, San Jose
    • Neurology – Oregon Health & Science University
  • Fellowship

    • Neuroimmunology – Veterans Affairs Medical Center, Portland

Memberships and associations:

  • American Board of Neurology and Psychiatry, 1985


Elsevier pure profile


  • {{ pub.journalAssociation.journal.name.text[0].value }}